Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

APTBIO of Shanghai Completes $28 Million Round for Proteomics Services

publication date: Apr 23, 2020

APTBIO, a Shanghai proteomic services company, completed a $28 million Series A financing, led by Luxin Venture Capital and Wuxi New District Investment Group. The company offers a broad portfolio of bio-analytical services to support drug discovery and preclinical development for biologics. APTBIO considers itself to be a pioneer in proteomics and metabolomics, Its proprietary platforms, based on mass spectrometry, offer biomarker discovery/validation services and innovative diagnostic tests. It provides proteomics, metabolomics and bioinformatics services to academic and commercial life science researchers. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China